Welcome to the world of immunohistochemistry!
📞 800-8581156 📧 info@naim.com.cn
Menu
  • Home
  • Product
  • Service and Support
    • Immunohistochemistry and Pathology
    • Immunohistochemistry Technology Exchange
    • Recommended List and Introduction of Newly Developed IHC
    • Public laboratory
    • Consultation and Feedback
  • News and Information
    • Hotspot Focus
    • Industry News
    • Maxxin Dynamics
    • Meeting Notice
  • Entering Maixin
    • Corporate Culture
    • Maisin Honors
    • Maixin Company Profile
    • Myriad Pathology Foundation Overview
  • Contact us
Close
分类
  • Consultation and Feedback
  • Hotspot Focus
  • Immunohistochemistry and Pathology
  • Immunohistochemistry Technology Exchange
  • Industry News
  • Maxxin Dynamics
  • Meeting Notice
  • News and Information
  • Public laboratory
  • Recommended List and Introduction of Newly Developed IHC
  • Service and Support
  • Uncategorized
Product Search
06 2 月
Hotspot Focus
Posted by author-avatar fzmaixinswy@163.com
6 2 月, 2026
0

Twenty-eighth Issue of “Mai Mai” Pathology Weekly Reading Notes | Overview of Immunohistochemical Markers for Lymphoid Tissue Tumor Diagnosis (Part 4)

Preface:In the first three installments of the lymphoma diagnosis series, we provided comprehensive explanations on commonly used immun...
Continue reading
06 2 月
Hotspot Focus
Posted by author-avatar fzmaixinswy@163.com
6 2 月, 2026
0

Common Molecular Marker for Glioma: BRAF V600E

Introduction:The BRAF V600E mutation is the most common mutation site of the BRAF gene and serves as a biomarker for targeted therapy w...
Continue reading
06 2 月
Hotspot Focus
Posted by author-avatar fzmaixinswy@163.com
6 2 月, 2026
0

New Applications of Antibodies // The Use of HNF1β in Ovarian Tumors

Preface:HNF1β, or hepatocyte nuclear factor 1β, is a transcription factor that plays an important role in organogenesis. It is not only...
Continue reading
06 2 月
Hotspot Focus
Posted by author-avatar fzmaixinswy@163.com
6 2 月, 2026
0

Proposed General Classification Framework for Squamous Cell Carcinoma

Introduction:Squamous cell carcinoma (SCC) is widely distributed in the skin and certain tracts (such as from the oral cavity to the es...
Continue reading
06 2 月
Hotspot Focus
Posted by author-avatar fzmaixinswy@163.com
6 2 月, 2026
0

Tumor Talk: Understanding Professional Terms in Pathology Reports

Introduction:The importance of pathology reports in tumor treatment is self-evident, but due to their highly specialized nature, many p...
Continue reading
06 2 月
Hotspot Focus
Posted by author-avatar fzmaixinswy@163.com
6 2 月, 2026
0

New Indicator for Pituitary Adenoma/PitNETs Classification: PIT-1

Introduction:In 2017, WHO established a clearer classification of primary adenohypophyseal tumors based on their cell line origin and h...
Continue reading
06 2 月
Hotspot Focus
Posted by author-avatar fzmaixinswy@163.com
6 2 月, 2026
0

Morphological Classification of Malignant Melanoma

Introduction:Malignant melanoma (MM) is a highly malignant tumor, commonly occurring in the skin and rarely in mucous membranes. The tu...
Continue reading
06 2 月
Hotspot Focus
Posted by author-avatar fzmaixinswy@163.com
6 2 月, 2026
0

Lynch Syndrome | The Predestined Inheritor

Introduction:Before getting to the serious matter, the editor will first tell a little story.There is a young man in the Netherlands wh...
Continue reading
06 2 月
Hotspot Focus
Posted by author-avatar fzmaixinswy@163.com
6 2 月, 2026
0

IHC Master’s Diary: Tissue Preprocessing – Fixation Chapter

Introduction:Immunohistochemistry has become an indispensable technical tool in clinical pathological diagnosis, providing important ev...
Continue reading
06 2 月
Hotspot Focus
Posted by author-avatar fzmaixinswy@163.com
6 2 月, 2026
0

What is the Epstein-Barr Virus? What are its risks?

Introduction:Autumn and winterCommon coldare high-incidence seasons. Many media platforms have started to call for and remind people to...
Continue reading
  • «
  • ‹
  • 10
  • 11
  • 12
  • 13
  • 14
  • ›
  • »

Copyright © 1993 - 2017 Fuzhou Maixin Biotechnology Development Co., Ltd. MinICP No. 05015562-1 | (Fujian) - Non-commercial - 2017-0010

  • Home
  • Product
  • Service and Support
    • Immunohistochemistry and Pathology
    • Immunohistochemistry Technology Exchange
    • Recommended List and Introduction of Newly Developed IHC
    • Public laboratory
    • Consultation and Feedback
  • News and Information
    • Hotspot Focus
    • Industry News
    • Maxxin Dynamics
    • Meeting Notice
  • Entering Maixin
    • Corporate Culture
    • Maisin Honors
    • Maixin Company Profile
    • Myriad Pathology Foundation Overview
  • Contact us
Sidebar